China's United Laboratories half-year profit drops 82%

United Laboratories International Holdings

31/08/2026 16:11

Overview
China pharmaceutical maker's half-year revenue fell 18% yr/yr
Net income attributable to owners dropped 82% yr/yr
Company did not declare interim dividend for the period

Outlook
Company did not provide specific guidance or outlook for the current or future periods

Result Drivers
GROSS PROFIT DECLINE - Co's gross profit fell sharply, reflecting lower revenue and higher cost of sales

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 6.17 bln
 
H1 Net Income Attributable
 
RMB 347.60 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for United Laboratories International Holdings Ltd is HK$14.75, about 72.8% above its August 28 closing price of HK$8.54
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago

Reuters Recommended Reads
Aug 31 - Hong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Aug 31 - China's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Aug 31 - China's Ascletis Pharma H1 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)